Suppr超能文献

促甲状腺素受体自身抗体与接受治疗的甲状腺功能正常的格雷夫斯病患者持续的促甲状腺素抑制有关。

Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.

作者信息

Brokken Leon J S, Wiersinga Wilmar M, Prummel Mark F

机构信息

Department of Endocrinology and Metabolism, University of Amsterdam, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands.

出版信息

J Clin Endocrinol Metab. 2003 Sep;88(9):4135-8. doi: 10.1210/jc.2003-030430.

Abstract

Antithyroid treatment effectively restores euthyroidism in patients with Graves' hyperthyroidism. After a few months of treatment, patients are clinically euthyroid with normal levels of thyroid hormones, but in many patients TSH levels remain suppressed. We postulated that TSH receptor autoantibodies could directly suppress TSH secretion, independently from thyroid hormone levels, via binding to the pituitary TSH receptor. To test this hypothesis, we prospectively followed 45 patients with Graves' hyperthyroidism who were treated with antithyroid drugs. Three months after reaching euthyroidism, blood was drawn for the analysis of thyroid hormones, TSH, and TSH binding inhibitory Ig (TBII) levels. After 6.7 +/- 1.5 months since start of antithyroid treatment, 20 patients still had detectable TBII levels, and 25 had become TBII negative. The two groups had similar levels of free T(4) and T(3), but TBII-positive patients had lower TSH values than TBII-negative patients: median 0.09 (range < 0.01-4.30) mU/liter vs. 0.84 (0.01-4.20; P = 0.015). In addition, TSH levels correlated only with TBII titers (r = -0.424; P = 0.004), and not with free T(4) or T(3) values. Our findings suggest that TBII suppress TSH secretion independently of thyroid hormone levels, most likely by binding to the pituitary TSH receptor.

摘要

抗甲状腺治疗可有效使格雷夫斯甲亢患者恢复甲状腺功能正常。治疗数月后,患者临床甲状腺功能正常,甲状腺激素水平也正常,但许多患者的促甲状腺激素(TSH)水平仍受到抑制。我们推测促甲状腺激素受体自身抗体可通过与垂体促甲状腺激素受体结合,独立于甲状腺激素水平直接抑制促甲状腺激素的分泌。为验证这一假设,我们对45例接受抗甲状腺药物治疗的格雷夫斯甲亢患者进行了前瞻性随访。甲状腺功能恢复正常3个月后,采集血样分析甲状腺激素、促甲状腺激素及促甲状腺激素结合抑制性免疫球蛋白(TBII)水平。自开始抗甲状腺治疗6.7±1.5个月后,20例患者的TBII水平仍可检测到,25例患者的TBII转为阴性。两组患者的游离T4和T3水平相似,但TBII阳性患者的促甲状腺激素值低于TBII阴性患者:中位数分别为0.09(范围<0.01 - 4.30)mU/升和0.84(0.01 - 4.20;P = 0.015)。此外,促甲状腺激素水平仅与TBII滴度相关(r = -0.424;P = 0.004),而与游离T4或T3值无关。我们的研究结果表明,TBII可独立于甲状腺激素水平抑制促甲状腺激素分泌,最可能是通过与垂体促甲状腺激素受体结合实现的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验